Advaxis, Inc. (NASDAQ:ADXS) insider Robert Petit sold 12,625 shares of Advaxis stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total transaction of $40,273.75. Following the sale, the insider now directly owns 237,265 shares of the company’s stock, valued at approximately $756,875.35. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.27). The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.43 million. Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/02/advaxis-inc-adxs-insider-robert-petit-sells-12625-shares.html.

A number of institutional investors have recently bought and sold shares of ADXS. Wells Fargo & Company MN lifted its position in Advaxis by 0.8% during the 1st quarter. Wells Fargo & Company MN now owns 43,669 shares of the biotechnology company’s stock worth $356,000 after acquiring an additional 360 shares during the period. Bank of New York Mellon Corp lifted its position in Advaxis by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 183,788 shares of the biotechnology company’s stock worth $1,501,000 after acquiring an additional 3,462 shares during the period. Swiss National Bank lifted its position in Advaxis by 17.5% during the 1st quarter. Swiss National Bank now owns 55,800 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 8,300 shares during the period. Parametric Portfolio Associates LLC lifted its position in Advaxis by 116.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 86,586 shares of the biotechnology company’s stock worth $707,000 after acquiring an additional 46,559 shares during the period. Finally, American International Group Inc. lifted its position in Advaxis by 7.6% during the 1st quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 1,459 shares during the period. 48.02% of the stock is owned by institutional investors.

Several analysts recently commented on the stock. Cantor Fitzgerald set a $19.00 target price on shares of Advaxis and gave the stock a “buy” rating in a report on Thursday, July 6th. BidaskClub raised shares of Advaxis from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Advaxis in a report on Friday, September 15th.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.